Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO Carl O'Donnell
SAN FRANCISCO (Reuters) - Eli Lilly and Co (LLY.N) aims to announce roughly one $1 billion to $5 billion deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products.
It will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, CFO John Smiley told Reuters in an interview at the JP Morgan Healthcare conference in San Francisco earlier this week.